CAS 28860-95-9

Carbidopa

Descripción:

Carbidopa es un compuesto farmacéutico utilizado principalmente en el tratamiento de la enfermedad de Parkinson y sus síntomas. Funciona como un inhibidor de la dopa descarboxilasa, lo que previene la conversión de levodopa a dopamina en los tejidos periféricos, aumentando así la disponibilidad de levodopa para el cerebro, donde puede convertirse en dopamina. Este mecanismo mejora los efectos terapéuticos de la levodopa mientras minimiza efectos secundarios como náuseas y vómitos. Carbidopa se administra a menudo en combinación con levodopa para mejorar la eficacia del tratamiento. El compuesto se caracteriza por su fórmula molecular, que incluye átomos de carbono, hidrógeno, nitrógeno y oxígeno. Se administra típicamente por vía oral y se absorbe bien en el tracto gastrointestinal. Carbidopa tiene un perfil de toxicidad relativamente bajo, pero puede causar efectos secundarios como mareos, boca seca o discinesia en algunos pacientes. Su farmacocinética implica una rápida absorción y una vida media relativamente corta, lo que requiere múltiples dosis a lo largo del día para un efecto terapéutico óptimo.

Fórmula: C₁₀H₁₄N₂O₄

InChI: InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1

Clave InChI: InChIKey=TZFNLOMSOLWIDK-JTQLQIEISA-N

SMILES: [C@@](CC1=CC(O)=C(O)C=C1)(C(O)=O)(NN)C

Sinónimos:

• (-)-<span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinamic acid
• (-)-<span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate
• (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinamic acid
• (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate
• (2S)-2-(Aminoazaniumyl)-3-(3,4-dihydroxyphenyl)-2-methylpropanoate
• (2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
• (S)-Carbidopa
• (αS)-α-Hydrazinyl-3,4-dihydroxy-α-methylbenzenepropanoic acid
• 1-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
• <span class="text-smallcaps">L</span>-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
• <span class="text-smallcaps">L</span>-Carbidopa
• <span class="text-smallcaps">L</span>-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
• <span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
• <span class="text-smallcaps">L</span>-α-Hydrazino-α-methyl-3,4-dihydroxyphenylpropionic acid
• <span class="text-smallcaps">L</span>-α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
• <span class="text-smallcaps">L</span>-α-Methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid
• <span class="text-smallcaps">L</span>-α-Methyl-α-hydrazino-β-(3,4-dihydroxyphenyl)propionic acid
• <span class="text-smallcaps">L</span>-α-Methyl-β-(3,4-dihydroxyphenyl)-α-hydrazinopropionic acid
• <span class="text-smallcaps">L</span>-α-Methyldopahydrazine
• Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (S)-
• Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-
• Cabidopa
• Carbidopa
• HMD
• Hydrazino-α-methyldopa
• Hydrocinnamic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, <span class="text-smallcaps">L</span>-
• Hydrocinnamic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, L-
• L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
• L-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
• L-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
• L-α-Hydrazino-α-methyl-3,4-dihydroxyphenylpropionic acid
• L-α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
• L-α-Methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid
• L-α-Methyl-α-hydrazino-β-(3,4-dihydroxyphenyl)propionic acid
• L-α-Methyl-β-(3,4-dihydroxyphenyl)-α-hydrazinopropionic acid
• L-α-Methyldopahydrazine
• Lodosin
• Lodosyn
• Mk 486
• N-Aminomethyldopa
• α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
• α-Methyldopahydrazine
• Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (αS)-
• L-alpha-Methyldopahydrazine
• 3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic acid
• Tocris-0455
• 1-(Mesithylene-2-sulfonyl)-3-nitro-1,2,4-triazole
• L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
• Carbidopum [INN-Latin]
• alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
• CCRIS 5093
• 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
• (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate (1:1)
• (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic acid
• SMR000058235
• NCGC00024596-01
• (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
• alpha-hydrazino-3,4-dihydroxy-alpha-methyl-(S )-
• Carbidopa anhydrous
• Benzenepropanoic acid
• alpha-Methyldopahydrazine
• L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic aci d
• alpha-HYDRAZINO-3,4-DIHYDROXY-alpha-METHYL-L-KINSON
• Hadrazino-alpha-methyldopa
• MLS000069628

Carbidopa Monohydrate

CAS: 28860-95-9, 38821-49-7

Fórmula: C₁₀H₁₄N₂O₄·H₂O

Pureza: >98.0%(T)(HPLC)

Forma y color: White to Light yellow powder to crystaline

Peso molecular: 244.25

Ref: 3B-C2450

3,3,3-trideuterio-2-[dideuterio-(3,4-dihydroxyphenyl)methyl]-2-hydrazinylpropanoic acid

CAS: 28860-95-9

Fórmula: C₁₀H₁₄N₂O₄

Pureza: 99%

Forma y color: Solid

Peso molecular: 226.2292

Ref: IN-DA00I5DW

Carbidopa

CAS: 28860-95-9

Carbidopa

Pureza: ≥98%

Peso molecular: 226.23g/mol

Ref: 54-BUP13336

(S)-3-(3,4-Dihydroxyphenyl)-2-Hydrazinyl-2-Methylpropanoic Acid

CAS: 28860-95-9

(S)-3-(3,4-Dihydroxyphenyl)-2-Hydrazinyl-2-Methylpropanoic Acid

Pureza: 97%

Peso molecular: 226.23g/mol

Ref: 54-OR1008689

Carbidopa

CAS: 28860-95-9

Fórmula: C₁₀H₁₄N₂O₄

Forma y color: White To Off-White Solid

Peso molecular: 226.23

Ref: 4Z-C-212

Carbidopa

CAS: 28860-95-9

Carbidopa (Lodosyn) is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM).

Fórmula: C₁₀H₁₄N₂O₄

Pureza: 98.01% - ≥98%

Forma y color: Solid

Peso molecular: 226.23

Ref: TM-T6795

(S)-(-)-Carbidopa

Producto controlado

CAS: 28860-95-9

Stability Unstable in Solution
Applications (S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA (D533751) for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.
References Henry, G.M. et al.: Psychosom. Med., 38, 95 (1976); Leguire, L.E. et al.: Invest. Ophthalmol. Vis. Sci. 34, 3090 (1993); Deleu, D. et al.: Naun. Schmied. Arch. Pharmacol. 348: 576 (1993);

Fórmula: C₁₀H₁₄N₂O₄

Forma y color: Neat

Peso molecular: 226.23

Ref: TR-C175985